HAEAMBIO Co., Ltd. aims to grow as a research-driven biopharmaceutical company specializing
in cardiovascular health by developing leading technologies for the diagnosis, treatment,
improvement and prevention of cardiovascular diseases, in order to overcome the rapidly
increasing unmet clinical needs resulting from the swift transition to an aging society.
Despite the rapidly increasing prevalence of cardiovascular diseases, three major diseases remain
unresolved. Our core technologies focused on developing new drugs for these three diseases and
conducting basic research aligned with the latest trends in cardiac interventions.
Calcific aortic valve disease (CAVD): Aortic stenosis
More View
Heart failure with preserved Ejection Fraction: HFpEF
More View
Heart Failure after Myocardial Infarction
More ViewHAEAMBIO Co., Ltd. leverages its network with leading hospitals and research institutes both
domestically and internationally to identify new targets for cardiovascular diseases. Based in this,
we have secured core technologies such as patient-derived valve cell isolation, gene profiling,
and the discovery and validation of calcification-related genes.
